New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Blueprint Medicines Corporation
http://www.blueprintmedicines.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Blueprint Medicines Corporation
Affordable PD-1 From China? CStone Going Global With EQRx Onboard
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
US FDA Heads Into October With Calm Approvals Forecast
Decision on Regeneron’s Ebola virus therapy, which uses a similar monoclonal antibody cocktail approach as the company’s COVID-19 therapy candidate, stands out among the 10 user fee goal dates in the coming month.
Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo
Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools